Sebaceous Hyperplasia



Sebaceous hyperplasia is a common, benign condition of sebaceous glands in adults of middle age or older. Lesions can be single or multiple and manifest as yellowish, soft, small papules on the face (particularly nose, cheeks, and forehead). Sebaceous hyperplasia occasionally also occurs on the chest,[1] areola,[2] mouth,[3] scrotum,[4] foreskin,[5] shaft of penis,[6] and vulva.[7, 8, 9] Rarely reported variants have included a giant form,[10] a linear or zosteriform arrangement, a diffuse form, and a familial form. Juxtaclavicular beaded lines are an additional variant characterized by closely placed papules arranged in parallel rows.[11] Lesions of sebaceous hyperplasia are benign, with no known potential for malignant transformation, but may be associated with nonmelanoma skin cancer in transplantation patients.[12, 13, 14]

Some authorities consider rhinophyma to represent a special form of sebaceous hyperplasia.

Typical facial papules appear in middle age, are larger than lesions on the areola or mouth, and display a central dell that corresponds to a central follicular infundibular ostium.


Sebaceous glands are found throughout the skin except on the palms and soles. They exist as a component of the pilosebaceous unit or, less frequently, open directly to the epithelial surface in areas of modified skin, including the lips and buccal mucosa (as Fordyce spots), glans penis or clitoris (as Tyson glands), areolae (as Montgomery glands), and eyelids (as meibomian glands). The largest sebaceous glands and the greatest number of sebaceous glands are found on the face, chest, back, and the upper outer arms.

These holocrine glands are composed of acini attached to a common excretory duct. The life cycle of the sebocytes, the cells that form the sebaceous gland, begins at the periphery of the gland in the highly mitotic basal cell layer; as the sebocytes differentiate and mature, they accumulate increasing amounts of lipid and migrate toward the central excretory duct. The mature sebocytes complete their life cycle as they reach the central duct and release their lipid content as sebum by disintegrating. The turnover time of the sebocytes as they migrate from the basal layer of the gland to the central duct is approximately 1 month.

Sebaceous glands are highly androgen sensitive, and, although the number of sebaceous glands remains approximately the same throughout life, their activity and size vary according to age and circulating hormone levels. The sebaceous glands, as well as the sweat glands, account for the vast majority of androgen metabolism in the skin.

The enzymes found in the sebocytes that are involved in androgen metabolism include 5-alpha-reductase type I, 3-beta-hydroxysteroid dehydrogenase, and 17-beta-hydroxysteroid dehydrogenase type II. These enzymes metabolize the relatively weak circulating androgens, such as dehydroepiandrosterone-sulfate, into the more potent androgens, such as dihydrotestosterone; these potent androgens, in turn, bind to receptors within the sebocytes, resulting in an increase in the size and metabolic rate of the sebaceous gland. Studies have shown that the activity of 5-alpha-reductase is higher in the scalp and facial skin than in other areas, so that testosterone and dihydrotestosterone stimulate more sebaceous gland proliferation in these areas. Estrogens have been found to decrease sebaceous gland secretion.

In the perinatal period, the sebaceous glands are initially large and are likely responsible for the production of vernix caseosa often seen in newborns; the activity and size of the sebaceous glands regress shortly after birth, due to withdrawal of maternal hormones, and remain small throughout infancy and childhood. At puberty, sebaceous glands enlarge and become increasingly active due to increased production of androgens, and they reach their maximum by the third decade of life. As androgen levels decrease with advancing age, the sebocyte turnover begins to slow down.

This decrease in cellular turnover results in crowding of primitive sebocytes within the sebaceous gland, causing a benign enlargement of the sebaceous gland, or sebaceous hyperplasia. This is particularly apparent in the areas where sebaceous glands are concentrated, such as the face. Although the hyperplastic glands are often inflated up to 10 times their normal size, they secrete very little sebum. In contrast to normal sebocytes that are engorged with lipid, the hyperplastic sebaceous glands contain small undifferentiated sebocytes with large nuclei and scant cytoplasmic lipid.

Sebaceous hyperplasia has also been linked to long-term immunosuppression in posttransplantation patients taking cyclosporin A. Although the mechanism for this reaction is poorly understood, this adverse effect is thought to be specific for the highly lipophilic cyclosporin A; other immunosuppressants have not been associated with an increased prevalence of sebaceous hyperplasia.

Although more commonly found in the older population, premature or familial cases have been reported in which younger individuals are affected with multiple lesions, suggesting a genetic predisposition. In these cases of premature familial sebaceous hyperplasia, extensive sebaceous hyperplasia appears at puberty and tends to progress with age.[15, 16, 17]



United States

Sebaceous hyperplasia is a common skin finding in aging adults, reported to occur in approximately 1% of the healthy population. However, the prevalence of sebaceous hyperplasia has been reported to be as high as 10-16% in patients receiving long-term immunosuppression with cyclosporin A.[18, 19, 20]


Sebaceous hyperplasia has no direct association with malignant degeneration and is not a cause of morbidity, except perhaps related to cosmesis. Sebaceous hyperplasia has been reported in association with internal malignancy in the setting of Muir-Torre syndrome. Muir-Torre syndrome is a rare autosomal dominant disorder in which visceral malignancies, sebaceous neoplasms (eg, sebaceous adenoma, sebaceous carcinoma), and keratoacanthoma coincide. Colon cancer is the leading internal malignancy associated with Muir-Torre syndrome, followed by hematologic malignancies.[21] Sebaceous hyperplasia alone does not signify a predisposition to cancer or represent a sign of Muir-Torre syndrome.

One study found that 29.9% of patients with a renal transplant had sebaceous hyperplasia; 45.7% of these patients had a history of nonmelanoma skin cancer, compared with 7.3% of patients without sebaceous hyperplasia.[13] This strong association of nonmelanoma skin cancer with sebaceous hyperplasia remained significant after correction of factors such as age, sex, skin type, and duration since the transplantation.


The difference in prevalence between men and women is unknown.


Sebaceous hyperplasia is common in newborns.[22] Of 1000 consecutive neonates examined in an Iranian prospective cohort study, 43.7% had sebaceous hyperplasia.[23]

Typical facial papules begin to appear in middle age (usually fifth or sixth decade) and continue to appear into later life.


Patients may be concerned for cosmetic reasons or may be worried about possible malignancy.


Sebaceous hyperplasia is often found incidentally upon examination.


Facial papular sebaceous hyperplasia is thought to be caused by a decrease in the circulating levels of androgen associated with aging. Ultraviolet radiation and immunosuppression have been postulated as cofactors in causing sebaceous hyperplasia. Ultraviolet radiation is considered only a cofactor, because sebaceous hyperplasia occasionally occurs on areas of the body where sunlight is not a relevant issue, including the buccal mucosa, areolae, and vulva.

Laboratory Studies

No laboratory studies are necessary. Biopsy is occasionally indicated to exclude basal cell carcinoma.

Histologic Findings

These lesions reveal discrete, enlarged glands. Within each gland, mature sebaceous lobules or acini surround and connect to a dilated central sebaceous duct. The lobules have one or more basal cell layers at their periphery, with undifferentiated sebocytes that contain large nuclei and scant cytoplasmic lipid, in contrast to normal sebocytes, which are engorged with lipid.

View Image

Normal sebaceous gland histology. Courtesy of Cooper Heard, MD.

View Image

Histology of sebaceous hyperplasia; enlarged sebaceous gland with multiple lobules grouped around a central dilated sebaceous duct. Courtesy of Cooper....

Medical Care

Sebaceous hyperplasia is completely benign and does not require treatment; however, lesions can be cosmetically unfavorable and sometimes bothersome when irritated. Treatments are mostly mechanical. Lesions tend to recur unless the entire unit is destroyed or excised. Risk of permanent scarring must be considered when treating benign lesions.

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Isotretinoin (Amnesteem, Claravis, Myorisan, Sotret)

Clinical Context:  Synthetic 13-cis isomer of naturally occurring tretinoin (trans -retinoic acid). Both agents are structurally related to vitamin A.

Decreases sebaceous gland size and sebum production. May inhibit sebaceous gland differentiation and abnormal keratinization. Used initially for severe cystic/scarring acne. Because of its action in reducing sebaceous gland size, used in sebaceous hyperplasia in lower doses than in acne.

Optimal dose and duration used to treat sebaceous hyperplasia not established. Clearance has been achieved within 2 wk in some patients. Others may take longer. Recurrence within 1 mo after stopping is common.

A US Food and Drug Administration–mandated registry is now in place for all individuals prescribing, dispensing, or taking isotretinoin. For more information on this registry, see iPLEDGE. This registry aims to further decrease the risk of pregnancy and other unwanted and potentially dangerous adverse effects during a course of isotretinoin therapy.

Class Summary

Isotretinoin has been used for sebaceous hyperplasia because of its ability to temporarily shrink sebaceous glands. Lesions return after discontinuation of therapy. Consider only for the most severe disfiguring cases in men or women who cannot become pregnant. Should only be prescribed by dermatologic experts in oral retinoid therapy.


Irritation or bleeding may occur if lesions are in an area prone to trauma (eg, friction by a comb or brush).


Sebaceous hyperplasia is benign.


Daniel J Hogan, MD, Clinical Professor of Internal Medicine (Dermatology), Nova Southeastern University College of Osteopathic Medicine; Investigator, Hill Top Research, Florida Research Center

Disclosure: Nothing to disclose.


R Walker Jones, MD, Harris M. Blackman, MD, LLC

Disclosure: Nothing to disclose.

Stephen H Mason, MD

Disclosure: Nothing to disclose.

Specialty Editors

Arash Taheri, MD, Research Fellow, Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Steven R Feldman, MD, PhD, Professor, Departments of Dermatology, Pathology and Public Health Sciences, Wake Forest University Health Sciences; Director, Center for Dermatology Research, Director, Psoriasis Treatment Center, Director of Industry Relations, Department of Dermatology, Wake Forest University School of Medicine

Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Galderma Honoraria Speaking and teaching; Taro Consulting fee Consulting; Ownership interest Management position; Causa Reseasrch Ownership interest Management position; Janssen Consulting; Pfizer Honoraria Speaking and teaching; Novartis Consulting fee Consulting; Celgene Consulting fee Consulting

Catherine M Quirk, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.


  1. Hogan DJ. Sebaceous hyperplasia of the chest. Int J Dermatol. Apr 1991;30(4):306. [View Abstract]
  2. Krisp A, Krause W. Areolar sebaceous hyperplasia. Acta Derm Venereol. 2003;83(1):61-2. [View Abstract]
  3. Daley TD. Intraoral sebaceous hyperplasia. Diagnostic criteria. Oral Surg Oral Med Oral Pathol. Mar 1993;75(3):343-7. [View Abstract]
  4. Ma HJ, Zhao G, Wang YX. Sebaceous hyperplasia of the scrotum in an adolescent boy. Pediatr Dermatol. May-Jun 2007;24(3):340-2. [View Abstract]
  5. Ena P, Origa D, Massarelli G. Sebaceous gland hyperplasia of the foreskin. Clin Exp Dermatol. Apr 2009;34(3):372-4. [View Abstract]
  6. Ju HY, Kim HS, Kim HO, Park YM. Sebaceous hyperplasia of the penile shaft. J Eur Acad Dermatol Venereol. Apr 2009;23(4):443-4. [View Abstract]
  7. Bakaris S, Kiran H, Kiran G. Sebaceous gland hyperplasia of the vulva. Aust N Z J Obstet Gynaecol. Feb 2004;44(1):75-6. [View Abstract]
  8. Malliah R, Gilhooly P, Lambert WC, Heller DS. Sebaceous hyperplasia of the vulva: case report and review of the literature. J Low Genit Tract Dis. Jan 2006;10(1):55-7. [View Abstract]
  9. Rocamora A, Santonja C, Vives R, Varona C. Sebaceous gland hyperplasia of the vulva: a case report. Obstet Gynecol. Sep 1986;68(3 Suppl):63S-65S. [View Abstract]
  10. Kato N, Yasuoka A. "Giant" senile sebaceous hyperplasia. J Dermatol. Apr 1992;19(4):238-41. [View Abstract]
  11. Finan MC, Apgar JT. Juxta-clavicular beaded lines: a subepidermal proliferation of sebaceous gland elements. J Cutan Pathol. Dec 1991;18(6):464-8. [View Abstract]
  12. Marini M, Saponaro A, Remorino L, Lynch P, Magarinos G. Eruptive lesions in a patient with bone marrow transplantation. Int J Dermatol. Feb 2001;40(2):133-5. [View Abstract]
  13. Salim A, Reece SM, Smith AG, et al. Sebaceous hyperplasia and skin cancer in patients undergoing renal transplant. J Am Acad Dermatol. Nov 2006;55(5):878-81. [View Abstract]
  14. de Berker DA, Taylor AE, Quinn AG, Simpson NB. Sebaceous hyperplasia in organ transplant recipients: shared aspects of hyperplastic and dysplastic processes?. J Am Acad Dermatol. Nov 1996;35(5 Pt 1):696-9. [View Abstract]
  15. Dupre A, Bonafe JL, Lamon P. Functional familial sebaceous hyperplasia of the face and premature sebaceous gland hyperplasia: a new and unique entity. J Am Acad Dermatol. Nov 1983;9(5):768-9. [View Abstract]
  16. Grimalt R, Ferrando J, Mascaro JM. Premature familial sebaceous hyperplasia: successful response to oral isotretinoin in three patients. J Am Acad Dermatol. Dec 1997;37(6):996-8. [View Abstract]
  17. Wang Q, Liu JM, Zhang YZ. Premature sebaceous hyperplasia in an adolescent boy. Pediatr Dermatol. Mar-Apr 2011;28(2):198-200. [View Abstract]
  18. Boschnakow A, May T, Assaf C, Tebbe B, Zouboulis ChC. Ciclosporin A-induced sebaceous gland hyperplasia. Br J Dermatol. Jul 2003;149(1):198-200. [View Abstract]
  19. Engel F, Ellero B, Woehl-Jaegle ML, Cribier B. [Diffuse sebaceous hyperplasia of the face induced by cyclosporine]. Ann Dermatol Venereol. Apr 2005;132(4):342-5. [View Abstract]
  20. McDonald SK, Goh MS, Chong AH. Successful treatment of cyclosporine-induced sebaceous hyperplasia with oral isotretinoin in two renal transplant recipients. Australas J Dermatol. Aug 2011;52(3):227-30. [View Abstract]
  21. Johnson PJ, Heckler F. Muir-Torre syndrome. Ann Plast Surg. Jun 1998;40(6):676-7. [View Abstract]
  22. Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr. Aug 2012;161(2):240-5. [View Abstract]
  23. Moosavi Z, Hosseini T. One-year survey of cutaneous lesions in 1000 consecutive Iranian newborns. Pediatr Dermatol. Jan-Feb 2006;23(1):61-3. [View Abstract]
  24. Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol. Dec 2004;140(12):1485-9. [View Abstract]
  25. Bryden AM, Dawe RS, Fleming C. Dermatoscopic features of benign sebaceous proliferation. Clin Exp Dermatol. Nov 2004;29(6):676-7. [View Abstract]
  26. Zaballos P, Ara M, Puig S, Malvehy J. Dermoscopy of sebaceous hyperplasia. Arch Dermatol. Jun 2005;141(6):808. [View Abstract]
  27. Oztas P, Polat M, Oztas M, Alli N, Ustun H. Bonbon toffee sign: a new dermatoscopic feature for sebaceous hyperplasia. J Eur Acad Dermatol Venereol. Nov 2008;22(10):1200-2. [View Abstract]
  28. Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clin Dermatol. Jan-Feb 2006;24(1):16-25. [View Abstract]
  29. Horio T, Horio O, Miyauchi-Hashimoto H, Ohnuki M, Isei T. Photodynamic therapy of sebaceous hyperplasia with topical 5-aminolaevulinic acid and slide projector. Br J Dermatol. Jun 2003;148(6):1274-6. [View Abstract]
  30. Bader RS, Scarborough DA. Surgical pearl: intralesional electrodesiccation of sebaceous hyperplasia. J Am Acad Dermatol. Jan 2000;42(1 Pt 1):127-8. [View Abstract]
  31. Rosian R, Goslen JB, Brodell RT. The treatment of benign sebaceous hyperplasia with the topical application of bichloracetic acid. J Dermatol Surg Oncol. Nov 1991;17(11):876-9. [View Abstract]
  32. Aghassi D, Gonzalez E, Anderson RR, Rajadhyaksha M, Gonzalez S. Elucidating the pulsed-dye laser treatment of sebaceous hyperplasia in vivo with real-time confocal scanning laser microscopy. J Am Acad Dermatol. Jul 2000;43(1 Pt 1):49-53. [View Abstract]
  33. Walther T, Hohenleutner U, Landthaler M. [Sebaceous gland hyperplasia as a side effect of cyclosporin A. Treatment with the CO2 laser]. Dtsch Med Wochenschr. Jun 19 1998;123(25-26):798-800. [View Abstract]
  34. Yu C, Shahsavari M, Stevens G, Liskanich R, Horowitz D. Isotretinoin as monotherapy for sebaceous hyperplasia. J Drugs Dermatol. Jun 2010;9(6):699-701. [View Abstract]
  35. Davis TT, Calilao G, Fretzin D. Sebaceous hyperplasia overlying a dermatofibroma. Am J Dermatopathol. Apr 2006;28(2):155-7. [View Abstract]
  36. De Villez RL, Roberts LC. Premature sebaceous gland hyperplasia. J Am Acad Dermatol. May 1982;6(5):933-5. [View Abstract]
  37. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. Aug 2000;21(4):363-92. [View Abstract]
  38. Elder D, Elenitsas R, Ragsdale BD. Tumors of the epidermal appendages. In: Elder D, Elenitas R, Jaworsky C, Johnson B. Lever's Histopathology of the Skin. 8th ed. Philadelphia, Pa: Lippincott-Raven; 1997:719-46.
  39. Fernandez N, Torres A. Hyperplasia of sebaceous glands in a linear pattern of papules. Report of four cases. Am J Dermatopathol. Jun 1984;6(3):237-43. [View Abstract]
  40. Luderschmidt C, Plewig G. Circumscribed sebaceous gland hyperplasia: autoradiographic and histoplanimetric studies. J Invest Dermatol. Apr 1978;70(4):207-9. [View Abstract]
  41. Nomland R. Senile Sebaceous. Arch Dermatol Sypholol. 1930;22:1004-9.
  42. Requena L, Roo E, Sanchez Yus E. Plate-like sebaceous hyperplasia overlying dermatofibroma. J Cutan Pathol. Jun 1992;19(3):253-5. [View Abstract]
  43. Rulon DB, Helwig EB. Multiple sebaceous neoplasms of the skin: an association with multiple visceral carcinomas, especially of the colon. Am J Clin Pathol. Dec 1973;60(6):745-52. [View Abstract]
  44. Schirren CG, Jansen T, Lindner A, Kind P, Plewig G. Diffuse sebaceous gland hyperplasia. A case report and an immunohistochemical study with cytokeratins. Am J Dermatopathol. Jun 1996;18(3):296-301. [View Abstract]
  45. Sehgal VN, Bajaj P, Jain S. Sebaceous hyperplasia in youngsters. J Dermatol. Sep 1999;26(9):619-20. [View Abstract]
  46. Zouboulis CC, Boschnakow A. Chronological ageing and photoageing of the human sebaceous gland. Clin Exp Dermatol. Oct 2001;26(7):600-7. [View Abstract]

Normal sebaceous gland histology. Courtesy of Cooper Heard, MD.

Histology of sebaceous hyperplasia; enlarged sebaceous gland with multiple lobules grouped around a central dilated sebaceous duct. Courtesy of Cooper Heard, MD.

Normal sebaceous gland histology. Courtesy of Cooper Heard, MD.

Histology of sebaceous hyperplasia; enlarged sebaceous gland with multiple lobules grouped around a central dilated sebaceous duct. Courtesy of Cooper Heard, MD.